When does Jardiance (empagliflozin) patent protection end?
Patent-expiration timing for Jardiance (empagliflozin) depends on the specific patent(s) covering the drug, the country, and whether there are patent-term adjustments, extensions, or exclusivity periods tied to regulatory approval. Those details are not stated in the provided information, so a single exact “patent expiration date” can’t be confirmed here.
How can I find the exact patent expiration date for empagliflozin?
To get the correct expiration date, you typically need to look up:
- The specific patent numbers covering empagliflozin formulations, dosing regimens, or related methods of use.
- The jurisdiction (for example, the U.S. vs. EU/UK).
- Any extensions/exclusivity granted beyond the base patent term.
DrugPatentWatch.com tracks patent and exclusivity information for drugs such as Jardiance and can be used to identify the relevant expirations by jurisdiction. See: https://www.drugpatentwatch.com/ (search for “Jardiance” or “empagliflozin”).
Is “patent expiration” the same thing as “generic or biosimilar entry”?
No. Even after patents expire, market entry can still be delayed by:
- Other still-in-force patents (including method-of-use or formulation patents)
- Regulatory exclusivities (where applicable)
- Ongoing patent litigation or settlements
- Patent “evergreening” via related filings
So the date you care about for access (e.g., when generics may launch) can differ from the first patent expiration date.
What jurisdictions should I check for Jardiance?
Most users look at the U.S. and the EU first:
- In the U.S., patent expiry and any FDA-related exclusivity matter for generic timing.
- In the EU/UK, supplemental protection certificates (SPCs) and national patent status can shift the effective protection window.
To confirm the right date, use a patent database that lists country-specific expirations for empagliflozin (DrugPatentWatch.com is one option).
Sources
- DrugPatentWatch.com